The Tackling Men's Health Evaluation Study

Tackling Men’s Health is an intervention developed out of a partnership between the Department of Health, Leeds Rhinos Rugby League Club and Leeds Metropolitan University. The intervention was designed to target men attending Headingley Carnegie Stadium, with the aim of promoting engagement with health services and therefore promoting improved health and wellbeing. The primary aim of the of the Tackling Men’s Health study is to assess engagement in an intervention targeting men attending rugby matches. Secondary aims of the research study are to: To assess the barriers and facilitators associated with implementing a health promotion intervention targeting men attending rugby league games To examine the effect of a multi-component targeted intervention on men’s self reported engagement with health services To examine the effect of a multi-component targeted intervention on men’s awareness of key health issues To examine the effect of multi-component targeted intervention on men’s perceived health status The research study monitored the evolution of the Tackling Men’s Health intervention, which was delivered in sports settings over the course of the 2009 Engage Super league Rugby league season. Seven stakeholders and 20 men who attended Rugby league matches were interviewed to achieve a broad understanding of appropriateness of the processes used in the planning and delivery of the Tackling Men’s Health intervention

Matrix Metalloproteinase 1: Role in Sarcoma Biology

In carcinomas stromal cells participate in cancer progression by producing proteases such as MMPs. The expression MMP1 is a prognostic factor in human chondrosarcoma, however the role in tumor progression is unknown. Laser capture microdissection and In Situ hybridization were used to determine cellular origin of MMP1 in human sarcomas. A xenogenic model of tumor progression was then used and mice were divided in two groups: each harboring either the control or a stably MMP1 silenced cell line. Animals were sacrificed; the neovascularization, primary tumor volumes, and metastatic burden were assessed. LCM and RNA-ISH analysis revealed MMP1 expression was predominantly localized to the tumor cells in all samples of sarcoma (p = 0.05). The percentage lung metastatic volume at 5 weeks (p = 0.08) and number of spontaneous deaths secondary to systemic tumor burden were lower in MMP1 silenced cell bearing mice. Interestingly, this group also demonstrated a larger primary tumor size (p<0.04) and increased angiogenesis (p<0.01). These findings were found to be consistent when experiment was repeated using a second independent MMP1 silencing sequence. Prior clinical trials employing MMP1 inhibitors failed because of a poor understanding of the role of MMPs in tumor progression. The current findings indicating tumor cell production of MMP1 by sarcoma cells is novel and highlights the fundamental differences in MMP biology between carcinomas and sarcomas. The results also emphasize the complex roles of MMP in tumor progression of sarcomas. Not only does metastasis seem to be affected by MMP1 silencing, but also local tumor growth and angiogenesis are affected inversely